Achillion Pharmaceuticals Inc $6.85

down -0.43


31/7/2014 04:00 PM  |  NASDAQ : ACHN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ACHN Trend Analysis - it has underperformed the S&P 500 by 19%

Partner Headlines

  1. Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline

    Benzinga
  2. Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

    Benzinga
  3. Achillion

    IBD
  4. Achillion Could Win Idenix's Mystery Suitor: Analyst

    IBD
  5. Baird Comments On Achillion's Bullish Share Action

    Benzinga
  6. Benzinga's Top #PreMarket Losers

    Benzinga
  7. Benzinga's Top #PreMarket Losers

    Benzinga
  8. Achillion Gets Massive Price Target Hike On HCV Drugs

    IBD
  9. Achillion gets price target hike

    IBD
  10. Mid-Day Market Movers For Monday, June 16, 2014

    Benzinga
  11. Achillion Gets Massive Price Target Hike On HCV Drugs

    IBD
  12. Morning Market Movers

    Benzinga
  13. Maxim Group Significantly Raises Achillion's PT, Shares Soar +15%

    Benzinga
  14. Mid-Afternoon Market Update: Markets Reverse Early Loses; Oil Continues ...

    Benzinga
  15. Mid-Morning Market Update: Markets Mostly Flat; Priceline To Acquire OpenTable ...

    Benzinga
  16. Morning Market Losers

    Benzinga
  17. Benzinga's Top #PreMarket Losers

    Benzinga
  18. Benzinga's Top Upgrades

    Benzinga
  19. FDA lifts hold, Achillion soars

    IBD
  20. Mid-Afternoon Market Update; RadioShack Misses More Than Expected, BE Aerospace ...

    Benzinga
  21. Mid-Day Market Update: Francesca's Falls On Downbeat Results; Achillion ...

    Benzinga
  22. Achillion Forges Ahead With Hep C Program On FDA OK

    IBD
  23. Mid-Morning Market Update: Markets Open Lower; RadioShack Reports Wider ...

    Benzinga
  24. Morning Market Movers

    Benzinga
  25. Benzinga's Top #PreMarket Gainers

    Benzinga
  26. Top Healthcare Movers For June 9, 2014

    Benzinga
  27. Morning Market Movers

    Benzinga
  28. Hepatitis C Stocks Move After Idenix Rockets Up 235%

    Benzinga
  29. Benzinga's Top #PreMarket Gainers

    Benzinga
  30. Achillion Advances ACH-3422 Into Clinical Trial, Initiates Phase 2 Pilot ...

    Benzinga
  31. Morning Gainers for Friday, March 14, 2014

    Benzinga
  32. Benzinga's Top #PreMarket Gainers

    Benzinga
  33. Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones ...

    Benzinga
  34. Benzinga's Top #PreMarket Gainers

    Benzinga
  35. Benzinga's Top #PreMarket Gainers

    Benzinga
  36. Achillion's ACH-3422 Shows Compelling Preclinical Profile

    Benzinga
  37. Achillion Pharma Downgraded After Hepatitis C Setback

    IBD
  38. UPDATE: Piper Jaffray Downgrades Achillion Pharmaceuticals as Pipeline ...

    Benzinga
  39. Morning Market Losers

    Benzinga
  40. UPDATE: Bank of America Downgrades Achillion Pharmaceuticals Following ...

    Benzinga
  41. Benzinga's Top Downgrades

    Benzinga
  42. Achillion Pharma Announces Unable to Resolve Clinical Hold

    Benzinga
  43. These Three Speculative Companies Are Loved By Insiders and Institutions

    Benzinga
  44. Mid-Day Market Update: SolarCity Wins Big, SunPower Continues its Fall

    Benzinga
  45. Bank of America Merrill Lynch Reiterates Buy Rating, $13 PT on Achillion ...

    Benzinga
  46. Gilead Hep C Drug Meets Expectations In Phase 3 Trial

    IBD
  47. Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower

    Benzinga
  48. Achillion Provides Update on Clinical HCV Development Programs, Announces ...

    Benzinga
  49. Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  50. Achillion Pharmaceuticals Says Farewell to Single Digits

    SchaeffersResearch
Trading Center